Stock Taper 
Lantern Pharma Inc. is a Dallas-based biotech company utilizing AI, machine learning, and genomic data to develop cancer therapies, including LP-100, LP-300, LP-184, and ADC programs, with several in clinical and preclinical stages.
LP-284 is a clinical-stage, novel small molecule with a synthetic lethal mechanism targeting DNA repair deficiencies in cancers, recently receiving FDA Orphan Drug Designation for soft tissue sarcomas in January 2026.
Lantern Pharma announced that its AI-developed drug candidate, LP-184, successfully achieved all primary endpoints in its Phase 1a clinical trial for advanced solid tumors. The positive results, demonstrating a favorable safety profile and early signs of antitumor activity, led to a significant 10% increase in the company's stock price, highlighting strong investor confidence in its precision oncology platform.
In a significant strategic shift during 2025, Lantern Pharma began commercializing its proprietary RADR® AI platform. This move transitions the company from solely using its AI for internal drug discovery to also providing its advanced computational tools as a service to the broader scientific and biopharma community, creating a new potential revenue stream.
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received regulatory and IRB approvals in
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
 RNXT | $1.33 | COMPARE |
 ANVS | $1.15 | COMPARE |
 ELUT | $0.83 | COMPARE |
 TVRD | $1.07 | COMPARE |
 RVPH | $0.50 | COMPARE |
 CALC | $1.37 | COMPARE |
